Cass Entrepreneurship Fund has returned to back a $3.9m funding round for Raremark, which is working on delivering precision medicine for patients suffering from rare diseases.

UK-based patient-data platform Raremark raised £3m ($3.9m) in funding yesterday from investors including the Cass Entrepreneurship Fund, the venture capital fund based at City, University of London’s Cass Business School.
The round was co-led by AlbionVC and Ananda Ventures, and also featured Oltre Venture.
Raremark has developed a platform that connects patients suffering from rare diseases and helps educate them through easy-to-understand information on the latest research and treatment development for their condition.
Biopharmaceutical companies can use the platform to access anonymised, aggregate data and to recruit patients for clinical trials.
The funding will go towards the development of Raremark’s patient engagement and data analysis technology. The company’s long-term aim is to help accelerate the development of new treatments for rare diseases.
Raremark previously raised $980,000 in a seed round led by the Cass Entrepreneurship Fund in 2016.
Helen Reynolds, investment director at the Cass Entrepreneurship Fund, said: “Raremark gets to the root of the problems familiar to all pharmaceutical companies, by boosting the quality of trials and improving drug development with data-driven intelligence.
“We are very excited about the company’s potential to transform rare disease treatments.”